Edition:
United Kingdom

People: Health and Happiness (H&H) International Holdings Ltd (1112.HK)

1112.HK on Hong Kong Stock

45.80HKD
20 Aug 2018
Change (% chg)

HK$-0.25 (-0.54%)
Prev Close
HK$46.05
Open
HK$46.65
Day's High
HK$47.50
Day's Low
HK$45.65
Volume
815,700
Avg. Vol
1,272,587
52-wk High
HK$64.50
52-wk Low
HK$26.00

Luo, Fei 

Mr. Luo Fei is Executive Chairman of the Board, Chief Executive Officer of the Company. Mr. Luo was appointed as an executive Director on 30 April 2010, and is also a director of the Company’s subsidiaries Biostime International Investment Limited (“Biostime Investment”), Biostime Hong Kong Limited (“Biostime Hong Kong”), Parenting Power International Holdings Limited (“Parenting Power Holdings”), Parenting Power Investment Limited (“Parenting Power Investment”), Parenting Power Hong Kong Limited (“Parenting Power Hong Kong”), Mama100 International Holdings Limited (“Mama100 Holdings”), Mama100 International Investment Limited (“Mama100 Investment”), Mama100 Hong Kong Limited (“Mama100 Hong Kong”), BiosTime, Inc. (Guangzhou) (“Biostime Guangzhou”), BMcare Baby Products Inc. (Guangzhou) (“BMcare Guangzhou”), Biostime (Guangzhou) Education Management Inc. (“Biostime Education”), Guangzhou Hapai Information Technology Co., Ltd. (“Guangzhou Hapai”) and Adimil (Changsha) Nutrition Products Limited (“Changsha Adimil”). Mr. Luo was appointed as a director of the Company’s indirectly wholly-owned subsidiaries, namely, Biostime Healthy Australia Pty Ltd, Biostime Healthy Australia Holdings Pty Ltd, Biostime Healthy Australia Investment Pty Ltd, Swisse Wellness Group Pty Ltd, SWG Holdco Pty Ltd, S W International Pty Ltd, Swisse Wellness Pty Ltd. in September 2015, Swisse China Limited on 16 December 2015, Swisse Wellness (Guangzhou) Limited (“Swisse Guangzhou”) on 15 April 2016. Mr. Luo is also a director of Guangzhou Mama100 E-commerce Co., Limited (“Mama100 E-commerce”), a company controlled by the Group through a series of structure contracts. He is also the supervisor of the Company’s subsidiary Biostime (Guangzhou) Health Products Limited (“Biostime Health”).

Basic Compensation

Total Annual Compensation, CNY 7,311,000
Restricted Stock Award, CNY --
Long-Term Incentive Plans, CNY --
All Other, CNY 2,241,000
Fiscal Year Total, CNY 9,552,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --